Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
658
658
Abstract
was posted on the Web site and open for online discussion
from May 1 to June 30, 2007. There were several subsequent
drafts and online discussion periods (August 15 to September
30, 2007, and November 30 to December 15, 2007). The
documents underwent revision after each comment period
before reposting on the Web. The 2-day live conference in
October 2007, attended by 154 registrants including pathologists, endocrinologists, surgeons, and radiologists, gave the
committees an in-depth opportunity to present their conclusions and debate controversial areas.
Nondiagnostic or Unsatisfactory
Every thyroid FNA must be evaluated for adequacy.
Inadequate samples are reported as nondiagnostic (ND) or
unsatisfactory (UNS). This category applies to specimens
that are unsatisfactory owing to obscuring blood, overly thick
smears, air drying of alcohol-fixed smears, or an inadequate
number of follicular cells. For a thyroid FNA specimen to be
satisfactory for evaluation (and benign), at least 6 groups of
benign follicular cells are required, each group composed of at
least 10 cells.6,7 The minimum size requirement for the groups
allows one to determine (by the evenness of the nuclear spacing) whether they represent fragments of macrofollicles.
There are several exceptions to the numeric requirement
of benign follicular cells. Any specimen that contains abundant colloid is considered adequate (and benign), even if 6
groups of follicular cells are not identified: A sparsely cellular
specimen with abundant colloid is, by implication, a predominantly macrofollicular nodule and, therefore, almost certainly
benign. Whenever a specific diagnosis (eg, lymphocytic
thyroiditis) can be rendered and whenever there is any atypia,
the specimen is, by definition, adequate for evaluation. ND/
UNS results occur in 2% to 20% of cases but ideally should
be limited to no more than 10% of thyroid FNAs, excluding
samples composed exclusively of macrophages.8-10
Specimens that consist only of cyst contents (macrophages)
are problematic. Many laboratories have traditionally considered
a macrophages-only sample unsatisfactory and included them in
the ND/UNS category, with the understanding that, because the
DOI: 10.1309/AJCPPHLWMI3JV4LA
659
659
Table 1
The Bethesda System for Reporting Thyroid Cytopathology: Recommended Diagnostic Categories*
I.
II.
III.
IV.
V.
VI.
Table 2
The Bethesda System for Reporting Thyroid Cytopathology: Implied Risk of Malignancy and Recommended Clinical
Management
Diagnostic Category
Usual Management
Nondiagnostic or Unsatisfactory
Benign
Atypia of Undetermined Significance or Follicular Lesion
of Undetermined Significance
Follicular Neoplasm or Suspicious for a Follicular Neoplasm
Suspicious for Malignancy
1-4
0-3
~5-15
15-30
60-75
Malignant
97-99
Surgical lobectomy
Near-total thyroidectomy or surgical
lobectomy
Near-total thyroidectomy
Nondiagnostic or Unsatisfactory
Cyst fluid only
Virtually acellular specimen
Other (obscuring blood, clotting artifact, etc)
Benign
Consistent with a benign follicular nodule (includes adenomatoid nodule, colloid nodule, etc)
Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context
Consistent with granulomatous (subacute) thyroiditis
Other
Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance
Follicular Neoplasm or Suspicious for a Follicular Neoplasm
Specify if Hrthle cell (oncocytic) type
Suspicious for Malignancy
Suspicious for papillary carcinoma
Suspicious for medullary carcinoma
Suspicious for metastatic carcinoma
Suspicious for lymphoma
Other
Malignant
Papillary thyroid carcinoma
Poorly differentiated carcinoma
Medullary thyroid carcinoma
Undifferentiated (anaplastic) carcinoma
Squamous cell carcinoma
Carcinoma with mixed features (specify)
Metastatic carcinoma
Non-Hodgkin lymphoma
Other
Benign
DOI: 10.1309/AJCPPHLWMI3JV4LA
661
661
Appendix 1
Bethesda Thyroid Atlas Contributors
Lester J. Layfield, MD, Department of Pathology, University of
Utah Hospital and Clinics, Salt Lake City
Virginia A. LiVolsi, MD, Department of Pathology and Laboratory
Medicine, University of Pennsylvania Medical Center,
Philadelphia
Britt-Marie E. Ljung, MD, Department of Pathology, University of
California San Francisco
Claire W. Michael, MD, Department of Pathology, University of
Michigan Medical Center, Ann Arbor
Ritu Nayar, MD, Department of Pathology, Northwestern University,
Feinberg School of Medicine, Chicago, IL
Yolanda C. Oertel, MD, Department of Pathology, Washington
Hospital Center, Washington, DC
Martha B. Pitman, MD, Department of Pathology, Massachusetts
General Hospital, Boston
Celeste N. Powers, MD, PhD, Department of Pathology, Medical
College of Virginia Hospitals, Virginia Commonwealth University
Medical Center, Richmond
Stephen S. Raab, MD, Department of Pathology, University of
Colorado at Denver, UCDHSC Anschutz Medical Campus, Aurora
Andrew A. Renshaw, MD, Department of Pathology, Baptist
Hospital of Miami, Miami, FL
Juan Rosai, MD, Dipartimento di Patologia, Instituto Nazionale
Tumori, Milano, Italy
Miguel A. Sanchez, MD, Department of Pathology, Englewood
Hospital and Medical Center, Englewood, NJ
Vinod Shidham, MD, Department of Pathology, Medical College
of Wisconsin, Milwaukee
Mary K. Sidawy, MD, Department of Pathology, Georgetown
University Medical Center, Washington, DC
Gregg A. Staerkel, MD, Department of Pathology, the University
of Texas M.D. Anderson Cancer Center, Houston
Edward B. Stelow, MD, Department of Pathology, University of
Virginia Health System, Charlottesville
Jerry Waisman, MD, Department of Pathology, New York
University of Medicine, New York
Helen H. Wang, MD, DrPH, Department of Pathology, Beth IsraelDeaconess Medical Center, Boston, MA
Philippe Vielh, MD, PhD, Department of Pathology, Institut de
Cancerologie Gustave Roussy, Villejuif, France
Grace C. H. Yang, MD, Department of Pathology, Weill Medical
College of Cornell University, New York, NY
Matthew A. Zarka, MD, Department of Laboratory Medicine and
Pathology, Mayo Clinic Arizona, Scottsdale
DOI: 10.1309/AJCPPHLWMI3JV4LA
663
663
Malignant
The general category malignant is used whenever the
cytomorphologic features are conclusive for malignancy.
Descriptive comments that follow are used to subclassify
the malignancy and summarize the results of special studies, if any. Approximately 3% to 7% of thyroid FNAs have
conclusive features of malignancy, and most are papillary
carcinomas.10-13 Malignant nodules are usually removed by
thyroidectomy, with some exceptions (eg, metastatic tumors,
non-Hodgkin lymphomas, and undifferentiated carcinomas).
The positive predictive value of a malignant FNA interpretation is 97% to 99%.
Summary
References
1. Hamberger B, Gharib H, Melton LJ III, et al. Fine-needle
aspiration biopsy of thyroid nodules: impact on thyroid
practice and cost of care. Am J Med. 1982;73:381-384.
2. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment
of a multidisciplinary approach to thyroid nodule diagnostic
evaluation. Cancer. 2007;111:508-516.
3. Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid
Cytopathology. New York, NY: Springer. In press.
4. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic
terminology and morphologic criteria for cytologic diagnosis
of thyroid lesions: a synopsis of the National Cancer Institute
Thyroid Fine-Needle Aspiration State of the Science
Conference. Diagn Cytopathol. 2008;36:425-437.
5. Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer
Institute Thyroid Fine Needle Aspiration State of the
Science Conference: a summation. Cytojournal. 2008;5:6.
doi:10.1186/1742-6413-5-6.
6. Goellner JR, Gharib H, Grant CS, et al. Fine-needle
aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol.
1987;31:587-590.
664
664
DOI: 10.1309/AJCPPHLWMI3JV4LA
665
665